Zacks: Brokerages Anticipate Natera, Inc. (NTRA) Will Post Quarterly Sales of $56.73 Million
Wall Street brokerages expect Natera, Inc. (NASDAQ:NTRA) to announce $56.73 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Natera’s earnings. The lowest sales estimate is $54.40 million and the highest is $59.06 million. Natera posted sales of $53.89 million in the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Natera will report full-year sales of $56.73 million for the current fiscal year, with estimates ranging from $214.00 million to $223.13 million. For the next year, analysts forecast that the firm will report sales of $282.09 million per share, with estimates ranging from $271.70 million to $288.81 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The business had revenue of $53.60 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same quarter in the prior year, the company posted ($0.46) EPS. The business’s revenue for the quarter was up 3.1% on a year-over-year basis.
A number of research firms recently issued reports on NTRA. Morgan Stanley restated an “overweight” rating and issued a $16.00 target price (up from $13.00) on shares of Natera in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “buy” rating and set a $15.00 target price for the company in a report on Wednesday, October 11th. Cowen and Company restated a “buy” rating and issued a $14.00 target price on shares of Natera in a report on Friday, September 1st. BidaskClub upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, ValuEngine upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $16.20.
In related news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $12.54, for a total value of $1,504,800.00. Following the completion of the sale, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.57% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Virtu KCG Holdings LLC purchased a new stake in Natera in the second quarter valued at approximately $126,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Natera during the second quarter valued at approximately $151,000. Voya Investment Management LLC lifted its position in Natera by 17.8% during the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after buying an additional 2,212 shares in the last quarter. American International Group Inc. lifted its position in Natera by 7.1% during the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Natera by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock valued at $143,000 after buying an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 59.79% of the company’s stock.
Natera (NASDAQ NTRA) opened at 12.99 on Wednesday. The stock has a 50 day moving average of $13.07 and a 200 day moving average of $13.07. The firm’s market capitalization is $691.37 million. Natera has a one year low of $7.35 and a one year high of $14.76.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.